Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bio-Techne Corp (NASDAQ:TECH)

123.88
Delayed Data
As of 3:59pm ET
 -0.37 / -0.30%
Today’s Change
95.68
Today|||52-Week Range
125.41
+20.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.6B

Company Description

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through three segments include: Biotechnology, Protein Platforms, and Diagnostics Divisions. The Biotechnology segment is a suppliers of specialized proteins, such as cytokines, growth factors, immunoassays, antibodies and related reagents, to the biotechnology research community. The Protein Platforms segment develops and manufactures instrumentation and related consumables designed to simplify protein analysis processes along with single cell protein analysis, all under the ProteinSimple brand. The Diagnostics Divisions segment serves the clinical markets with regulated products such as controls, calibrators, reagents and immunoassays intended for diagnostic uses. The company was founded on July 17, 1981 and is headquartered in Minneapolis, MN.

Contact Information

Bio-Techne Corp.
614 McKinley Place NE
Minneapolis Minnesota 55413-2610
P:(612) 379-2956
Investor Relations:
(646) 277-1266

Employees

Shareholders

Mutual fund holders58.63%
Other institutional42.31%
Individual stakeholders0.58%

Top Executives

Charles R. KummethPresident, Chief Executive Officer & Director
James T. HippelCFO, Chief Accounting Officer & VP-Finance
J. Fernando BazanChief Technology Officer
Brenda S. FurlowSecretary, Senior Vice President & General Counsel
Norman David EansorSenior Vice President